Mineralys Therapeutics, Inc.
lorundrostat
hypertension
Resolved
120days ago
Phase 2 readout · Mar 9, 2026
What's at stake
Phase 2 trial results for lorundrostat in hypertension are due Mar 9, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 16h ago
“On March 9, 2026, the Company issued a press release announcing topline results from the Phase 2 Explore-OSA exploratory trial.”